Biotech

Previewing EXACT Sciences Corporation (NASDAQ: EXAS)'s second-quarter results, Canaccord Genuity said it expects the company to deliver another strong quarter, extending its strong commercial momentum. The firm indicated that the company remains one of its top picks for 2017.   Strong...

Johnson & Johnson (NYSE: JNJ) shares are up about 20 percent since the company acquired Actelion back in January. However, despite the strong performance, Credit Suisse analyst Vamil Divan sees more upside ahead for the pharma giant. On Thursday, Credit Suisse reinstated coverage of Johnson...

Sarepta Therapeutics Inc (NASDAQ: SRPT) is trading up more than 20 percent Thursday after a second-quarter beat that included $35 million in sales of its Duchenne muscular dystrophy drug, Exondys 51, against a consensus of $23 million. The Cambridge-based biopharma company has increased its full-...

Previewing second-quarter results of Pfizer Inc. (NYSE: PFE), Credit Suisse prescribed a Neutral rating for the shares of the company, down from its previous Outperform rating. Pfizer is scheduled to release its second-quarter results at 7 a.m. ET on Aug. 1. Analysts led by Vamil Divan expect...

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares jumped up over 17 percent during Wednesday’s after-hours trading sessions, after the medical research and drug development company crushed earnings estimates. A Closer Look At Q2 Earnings Revenue: $35 million (consensus estimate was $22.3...

The U.S. Food and Drug Administration on Monday approved Puma Biotechnology Inc (NASDAQ: PBYI)'s NERLYNX (neratinib), formerly known as PB272, for the treatment of breast cancer. Neratinib is the first anti-HER2 treatment to gain the FDA's approval for extended adjuvant therapy for early-...

Earnings season for the biotech and pharma sector kicks off this week with industry bellwether Johnson & Johnson JNJ reporting second quarter results tomorrow before the market opens. Swiss pharma giant, Novartis NVS, which was in the news recently related to a favorable FDA advisory panel...

Verastem Inc (NASDAQ: VSTM) stock had a relatively flat month in June despite the firm’s presentation of positive follow-up data for its DYNAMO study of Duvelisib, its PI3K-delta and gamma inhibitor for patients with follicular lymphoma (FL), small lymphocytic lymphoma (SLL), and marginal...

Like most witnesses of today’s booming tech scene, OCTANe is drawn to the buzzword “innovation.” The Orange County, California, firm, positioned to capitalize on the region known for graduating record engineering classes, looks to help drive growth by facilitating connections...

Shares of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) is clinical-stage biopharmaceutical company whose lead pivotal-stage product candidate, eptinezumab, is used for the treatment of migraines. The company is also one that ordinary investors should consider passing on, according to CNBC's Jim...

Big bank earnings dominate the proceedings today, and what we saw looked pretty good as results pointed to a healthy consumer. Credit card divisions and business loans sent positive signals, even as trading revenue came in a little light. JPMorgan Chase & Co. (NYSE: JPM), Wells Fargo & Co (...

Johnson & Johnson JNJ, a healthcare bellwether, will report second-quarter 2017 results on Jul 18, before the opening bell. Last quarter, the company reported a positive earnings surprise of 3.39%. J&J's shares  have gained 13.9% so far this year, significantly ahead of the 10.8%...

Investors in Paratek Pharmaceuticals, Inc. PRTK need to pay close attention to the stock based on moves in the options market lately. That is because the July 21st, 2017 $22.50 Put had some of the highest implied volatility of all equity options today. Investors in Paratek Pharmaceuticals, Inc....

Shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) soared higher by more than 25 percent on Tuesday in reaction to the company's announcement that there is now a clear path to approval for its migalastat NDA therapy. Amicus suffered a major setback for its therapy in November, 2016 when the U.S....

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares are on a roll on Tuesday, rising by about one-half on over 10 times their average volume. The stock is now trading at its highest level in nearly two years. For those keen to the know the reason behind the jump, here are the details. Catalyst...